6 August 2012
by GLDMDG
0 comments

2013 GLDMDG Meeting

Next year’s GLDMDG meeting is scheduled to take place on May 9th and 10th at the Hilton Hotel in Toledo, Ohio.  Additional information about the meeting and an updated sponsorship prospectus will be posted in the coming months.

kalamazoo_radisson

15 June 2012
by GLDMDG
0 comments

2012 Meeting Schedule

Radisson Plaza Hotel at Kalamazoo Center

Kalamazoo, Michigan
May 3-4, 2011

Meeting Booklet Adobe Reader icon

Thursday, May 3, 2012

Registration, Continental Breakfast, Poster Setup, and Sponsor Booth Setup., 10:00 AM

Welcome., 11:00 AM

In Vitro Approaches to Assess the Enzyme-Suppressing Effects of Therapeutic Proteins., 11:10 AM
Andrew Parkinson, Ph.D.,CEO, XPD Consulting, Shawnee, KS.

Probing P450 Structure-Function Relationships using X-ray Crystallography., 11:50 AM
Eric Johnson, Ph.D., Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA.

Lunch, Poster Viewing, and Sponsor Booths, 12:30 PM

Clarifying the Importance of CYP2C19 and PON1 in the Mechanism of Clopidogrel Bioactivation and In Vivo Antiplatelet Response., 2:00 PM
Romel Tirona, Ph.D, Assistant Professor, Division of Clinical Pharmacology, Departments of Physiology & Pharmacology and Medicine, The University of Western Ontario, London, Ontario, Canada.

Evaluation of Absorption Mediated Drug-Drug Interactions in the Oncology Setting., 2:40 PM
Joseph Ware, Ph.D., Senior Scientist, Clinical Pharmacology, Genentech, South San Francisco, CA.

Break, 3:20 PM

Nuclear Receptor Regulation of Hydroxysteroid Sulfotransferase (SULT2A): Implications for Metabolic Disease Mechanisms., 3:40 PM
Melissa Runge-Morris, M.D., Director, Institute of Environmental Health Sciences, Wayne State University, Detroit, MI.

Modeling Enzyme-Substrate Interactions of CYP2A6 and CYP2A6*18., 4:20 PM
Patrick Kane, Graduate Student, Walsh University, North Canton, OH.

Mechanism-based Inactivation of Human Cytochrome P450 2B6 by Chlorpyrifos., 4:40 PM
Jaime D’Agostino, Post-Doc, University of Michigan, Ann Arbor, MI.

Poster Session (Author Available), Sponsor Booths, and Mixer, 5:00 PM

Dinner, 7:00 PM

 

Friday, May 4, 2012

GLDMDG Business Meeting and Sponsor Booth Setup, 7:30 AM

Continental Breakfast and Poster Viewing, 8:00 AM

Metabolite Identification by High Resolution Mass Spectrometry in High Throughput Drug Discovery Settings., 9:00 AM
Jianwei Shen, Ph. D., Senior Scientist, Drug Metabolism, Abbott Laboratories, Abbott Park, IL.

NMR as a Tool in Mitigating Metabolism Issues in Early Discovery., 9:35 AM
Gregory Walker, Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer,
Inc., Groton, CT.

Break, 10:10 AM

Application of PBPK Modeling to Drug Discovery., 10:30 AM
Daniel Mudra, Ph.D., Senior Research Scientist, Eli Lilly and Company, Indianapolis, IN.

The Principles of Human Food Safety with Respect to the Development, Commercialization, Evolution (and Metabolism) of Ceftiofur., 11:05 AM
David Gottschall, Ph.D., Research Fellow, Veterinary Medicine Research & Development, Pfizer Animal Health, Kalamazoo, MI.

Closing Remarks, 11:40 AM

2012_meeting_schedule

28 March 2012
by GLDMDG
0 comments

2012 Meeting Schedule

Radisson Plaza Hotel at Kalamazoo Center

Kalamazoo, Michigan
May 3-4, 2012

Thursday, May 3, 2012

Registration, Continental Breakfast, Poster Setup, and Sponsor Booth Setup, 10:00 AM

Welcome, 11:00 AM

In Vitro Approaches to Assess the Enzyme-Suppressing Effects of Therapeutic Proteins., 11:10 AM
Andrew Parkinson, Ph.D.,CEO, XPD Consulting, Shawnee, Kansas.

Probing P450 Structure-Function Relationships using X-ray Crystallography., 11:50 AM
Eric Johnson, Ph.D., Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California.

Lunch, Poster Viewing, and Sponsor Booths, 12:30 PM

Clarifying the Importance of CYP2C19 and PON1 in the Mechanism of Clopidogrel Bioactivation and In Vivo Antiplatelet Response., 2:00 PM
Romel Tirona, Ph.D, Assistant Professor, Division of Clinical Pharmacology, Departments of Physiology & Pharmacology and Medicine, The University of Western Ontario, London, Ontario, Canada.

Evaluation of Absorption Mediated Drug-Drug Interactions in the Oncology Setting., 2:40 PM
Joseph Ware, Ph.D., Senior Scientist, Clinical Pharmacology, Genentech, South San Francisco, California.

Break, 3:20 PM

Nuclear Receptor Regulation of Hydroxysteroid Sulfotransferase (SULT2A): Implications for Metabolic Disease Mechanisms., 3:40 PM
Melissa Runge-Morris, M.D., Director, Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan.

Selected graduate student presentation., 4:20 PM

Selected post-doc presentation., 4:40 PM

Poster Session (Author Available), Sponsor Booths, and Mixer, 5:00 PM

Dinner, 7:00 PM

 

Friday, May 4, 2012

GLDMDG Business Meeting and Sponsor Booth Setup, 7:30 AM

Continental Breakfast and Poster Viewing, 8:00 AM

Metabolite Identification by High Resolution Mass Spectrometry in High Throughput Drug Discovery Settings., 9:00 AM
Jianwei Shen, Ph. D., Senior Scientist, Drug Metabolism, Abbott Laboratories, Abbott Park, Illinois.

NMR as a Tool in Mitigating Metabolism Issues in Early Discovery., 9:35 AM
Gregory Walker, Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Groton, Connecticut.

Break, 10:10 AM

Application of PBPK Modeling to Drug Discovery., 10:30 AM
Daniel Mudra, Ph.D., Senior Research Scientist, Eli Lilly and Company, Indianapolis, Indiana.

The Principles of Human Food Safety with Respect to the Development, Commercialization, Evolution (and Metabolism) of Ceftiofur., 11:05 AM
David Gottschall, Ph.D., Research Fellow, Veterinary Medicine Research & Development, Pfizer Animal Health, Kalamazoo, Michigan.

Closing Remarks, 11:40 AM

poster_session

22 March 2012
by GLDMDG
0 comments

Poster Presentation Deadline

One graduate student and one post-doc will be nominated by the GLDMDG steering committee to give oral presentations of their poster contents. To be considered, a poster must be submitted at the online registration site (http://www.regonline.com/gldmdg2012) by Friday, April 6th. Nominated presenters will be notified by a GLDMDG committee member no later than Friday, April 13th.

Poster size information, a PowerPoint template, and a tentative schedule can be found at http://www.greatlakesdmdg.org/?p=290.

registration

3 March 2012
by GLDMDG
0 comments

Online Registration is Now Open

Online registration for the 2012 GLDMDG meeting is available at http://www.regonline.com/gldmdg2012.

Speakers

Confirmed talks for our 7th annual meeting include:

In Vitro Approaches to Assess the Enzyme-Suppressing Effects of Therapeutic Proteins.
Andrew Parkinson, Ph.D.,CEO, XPD Consulting, Shawnee, Kansas.

Probing P450 Structure-Function Relationships using X-ray Crystallography.
Eric Johnson, Ph.D., Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California.

Clarifying the Importance of CYP2C19 and PON1 in the Mechanism of Clopidogrel Bioactivation and In Vivo Antiplatelet Response.
Romel Tirona, Ph.D, Assistant Professor, Division of Clinical Pharmacology, Departments of Physiology & Pharmacology and Medicine, The University of Western Ontario, London, Ontario, Canada.

Evaluation of Absorption Mediated Drug-Drug Interactions in the Oncology Setting.
Joseph Ware, Ph.D., Senior Scientist, Clinical Pharmacology, Genentech, South San Francisco, California.

Nuclear Receptor Regulation of Hydroxysteroid Sulfotransferase (SULT2A): Implications for Metabolic Disease Mechanisms.
Melissa Runge-Morris, M.D., Director, Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan.

Metabolite Identification by High Resolution Mass Spectrometry in High Throughput Drug Discovery Settings.
Jianwei Shen, Ph. D., Senior Scientist, Drug Metabolism, Abbott Laboratories, Abbott Park, Illinois.

NMR as a Tool in Mitigating Metabolism Issues in Early Discovery.
Gregory Walker, Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Groton, Connecticut.

Application of PBPK Modeling to Drug Discovery.
Daniel Mudra, Ph.D., Senior Research Scientist, Eli Lilly and Company, Indianapolis, Indiana.

The Principles of Human Food Safety with Respect to the Development, Commercialization, Evolution (and Metabolism) of Ceftiofur.
David Gottschall, Ph.D., Research Fellow, Veterinary Medicine Research & Development, Pfizer Animal Health, Kalamazoo, Michigan.

Registration Fees

Registration Type Fee ($USD)
Standard 100
Student/Postdoc with Poster (must be primary presenter) 0
Student/Postdoc 50

Poster Information

Poster size information, a PowerPoint template, and a tentative schedule can be found at http://www.greatlakesdmdg.org/?p=290.

In addition to the opportunity of presenting a poster, one graduate student and one post-doc will be nominated by the GLDMDG steering committee to give oral presentations of their poster contents. To be considered, a poster must be submitted at the online registration site (http://www.regonline.com/gldmdg2012) by Friday, April 6th. Nominated presenters will be notified by a GLDMDG committee member no later than Friday, April 13th.

Hotel Information

A block of rooms has been reserved at the Radisson Plaza Hotel at Kalamazoo Center for the GLDMDG meeting . Select the Great Lakes Drug Metabolism Di-STD1 rate at http://www.radisson.com/greatlakesmetabolismdiscussion to reserve a room at the discounted rate of $125.00 (plus tax) per night. Other room types are available at higher costs.

Area Activities

The Kalamazoo area offers various things to see and do. Links to area attractions are listed below.